<DOC>
	<DOCNO>NCT00001968</DOCNO>
	<brief_summary>This study examine safety give antiviral therapy HIV infection once-daily dose schedule , assess well patient tolerate regimen . A day dose schedule may easier people follow one require take medicine 2 3 time day . The ease treatment important , follow prescribed dose regimen may make therapy less effective ineffective . HIV-infected patient 18 year old never treat infection may eligible study . Candidates screen history physical examination , include blood test . Participants take following medication day : 1200 mg amprenavir ( 8 capsule ) ; 300 mg ritonavir ( 3 capsule ) ; 600 mg abacavir ( 2 pill ) ; 300 mg lamivudine ( 2 pill ) . Patients routine blood test see nurse doctor , , follow-up visit week 2 , 4 , 8 , 12 , 16 ; every 8 week week 48 ; every 3 month 3 year . At week 2 , special blood test do course day measure blood drug level . For test , blood sample draw 8 time 24-hour period . A heparin lock ( device allow needle remain vein ) use avoid multiple needle stick .</brief_summary>
	<brief_title>Once-Daily Drug Regimen HIV-Infected Patients</brief_title>
	<detailed_description>The development once-daily anti-retroviral regimen priority regimen simplicity might enhance regimen adherence , once-daily regimen would useful directly observe therapy . Pharmacokinetic modeling suggest plasma level amprenavir presence ritonavir , potent inhibitor cytochrome p450 , high enough support once-daily dose . Lamivudine currently explore study once-daily dose . Abacavir use daily vitro study suggest dose might appropriate . In uncontrolled , open-label study , amprenavir 1200 mg daily , ritonavir 300 mg daily , lamivudine 300 mg daily , abacavir 600 mg daily administer 25 HIV-infected , anti-retroviral naive patient . The objective assess tolerability safety regimen ; plasma concentration amprenavir ; anti-viral response . Study evaluation include percentage patient discontinue regimen week 16 24 toxicity , intolerance failure ; number grade 3 4 adverse event week 16 24 ; antiviral response week 16 , 24 , 48 ( change baseline percentage patient viral load less 50 copy less 400 copy per mL ) , number ( percent ) patient trough plasma concentration amprenavir 280 ng/mL .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Amprenavir</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Adults ( great 18 year ) infect HIV1 . Plasma viral burden great 8,000 less 60,000 RNA copy per ml . bDNA method screening . CD4 cell count 200 cell per microliter screen . No prior treatment antiretroviral agent . Laboratory value screen : hemoglobin great 9 g per dl ; granulocyte count great 900 cell per microliter ; platelet count great 80,000 cell per microliter ; AST ( SGOT ) less 151 U/L ; creatinine le 2 mg/dL . Must pregnant breastfeeding willing avoid pregnancy use nonhormonal method birth control study participation . Pregnancy test ( blood urine ) must negative within two week prior dose study medication . Willing able provide write informed consent . No history suggestive malabsorption . No chronic diarrhea . Must treatment systemic corticosteroid great physiologic replacement dos , interleukin , interferon , radiation therapy cytotoxic chemotherapeutic agent within 30 day study drug administration anticipate need radiation chemotherapy treatment within next 48 week ( exception local treatment Kaposi 's sarcoma ) . Must current anticipated therapy agent document activity HIV1 vitro . Must active , untreated opportunistic infection major illness would , opinion investigator , increase risk adverse event might pose patient might render patient ill return study visit . Must significant substance abuse psychiatric illness might interfere assessment compliance . Must current anticipated future need follow drug contraindicate amprenavirritonavir regimen drugdrug interaction : Terfenadine ( Seldane ) , Astemizole ( Hismanal ) , Cisapride ( Propulsid ) , Triazolam ( Halcion ) , Bepridil ( Vascor ) , Medazolam ( Versed ) , Rifampin ( Rifadin , Rifamate , Rifater ) , Ergotamine/Dihydroergotamine contain regimen ( Ergomar , Wygraine , Ercaf , DHE , Migranal ) , Amiodarone ( Cordarone ) , Flecanaide ( Tambocor ) , Propafenone ( Rythmol ) , Quinidine ( Quinaglute , Cardioquin ) , Pimozide ( Orap ) . Must current anticipated future need follow anticonvulsant : phenobarbital , phenytoin , carbamazepine .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 1999</verification_date>
	<keyword>AIDS</keyword>
	<keyword>Anti-Retroviral Therapy</keyword>
	<keyword>Drug Interactions</keyword>
	<keyword>HIV</keyword>
	<keyword>Protease Inhibitor</keyword>
</DOC>